Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.36 |
| ▸ | PPARG | P37231 | 7/20 | 0.36 |
| ▸ | PPARD | Q03181 | 7/20 | 0.36 |
| ▸ | PPARA | Q07869 | 7/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17669644 | 1.00 | CYP1A2 (0.39) | CYP1A2AKR1B1GPR84PPARGPPARD | |
| SCHEMBL25278944 | 0.87 | CYP1A2 (0.41) | CYP1A2AKR1B1GPR84PPARGPPARD | |
| SCHEMBL28050301 | 0.81 | GAA (0.42) | — | |
| SCHEMBL11829345 | 0.79 | GPR84 (0.45) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL23533422 | 0.79 | GPR84 (0.45) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL11838734 | 0.79 | GPR84 (0.45) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL244829 | 0.78 | TSHR (0.50) | CYP1A2AKR1B1GPR84PPARGPPARD | |
| SCHEMBL8733717 | 0.76 | TSHR (0.48) | CYP1A2GPR84PPARGPPARDPPARA | |
| SCHEMBL23533471 | 0.76 | TSHR (0.44) | CYP1A2GPR84PPARGPPARDPPARA | |
| SCHEMBL8733702 | 0.76 | TSHR (0.48) | CYP1A2GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-26 | — | — | US | disclosed |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-05 | — | — | US | disclosed |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-20 | — | — | US | disclosed |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | US | disclosed |
| US-9790198-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-17 | — | — | US | disclosed |
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
| EP-3204361-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica N.V. (BE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057731-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102071-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | GPR119, GLP1R, GPR65 | CYP1A2 1711/4885AKR1B1 563/4885GPR84 7/4885 |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | GPR119, GLP1R, GPR65 | CYP1A2 1711/4885AKR1B1 563/4885GPR84 7/4885 |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR52, GPR65 | CYP1A2 1436/4885AKR1B1 771/4885GPR84 8/4885 |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | CYP1A2 1436/4885AKR1B1 771/4885GPR84 8/4885 |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | CYP1A2 1436/4885AKR1B1 771/4885GPR84 8/4885 |
| US-20160102071-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR52, GPR65 | CYP1A2 1436/4885AKR1B1 771/4885GPR84 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.